(NasdaqGM:TVGN),(NASDAQ:TVGNW), WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these […]
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure GlobeNewswire August 27, 2025 WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent
(NASDAQ:RMJAX),(NASDAQ:RMHVX),(NASDAQ:RMHIX), NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund Investors to Secure Counsel Before Important Deadline in Securities Class Action – RMJAX, RMHVX, RMHIX GlobeNewswire August 27, 2025 NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law
CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today announced it has entered into a collaboration with Mayo Clinic to develop novel therapeutics aimed at addressing unmet needs of patients with chronic graft-versus-host disease (GvHD). https://mma.prnewswire.com/media/2759571/CAGE_Bio_Logo.jpg Under this agreement, CAGE Bio and Mayo Clinic will
(NasdaqGM:ALT), NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT GlobeNewswire August 27, 2025 NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between
Johnson City, TN – IV infusion therapy is quickly becoming a sought-after wellness option across the country, and Johnson City is no exception. With a growing interest in natural ways to boost energy, improve hydration, and support immune health, local residents now have a trusted, professional option in Aspiral Healing. Led by Registered Nurse Amanda
(NYSE:ANRO), NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. LUND, SWEDEN /